Edition:
United Kingdom

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

0.70USD
19 Oct 2018
Change (% chg)

$0.01 (+1.02%)
Prev Close
$0.69
Open
$0.69
Day's High
$0.72
Day's Low
$0.69
Volume
80,646
Avg. Vol
214,036
52-wk High
$2.41
52-wk Low
$0.61

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $55.98
Shares Outstanding(Mil.): 22.48
Dividend: --
Yield (%): --

Financials

  CATB.OQ Industry Sector
P/E (TTM): -- 85.68 33.65
EPS (TTM): -1.74 -- --
ROI: -107.14 0.45 14.28
ROE: -117.90 1.37 16.00

BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

10 May 2018

BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data

* CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT

25 Apr 2018

Earnings vs. Estimates